June 14, 2021
Chugai Pharmaceutical said on June 11 that it has submitted a new drug application in Japan for faricimab, an anti-VEGF/anti-Ang-2 bispecific antibody, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), which are major causes...read more